Parental acceptance of an intranasal vaccine: Example of influenza vaccine

Background: Influenza vaccination coverage of children with chronic disease is insufficient in France, although a nasal live attenuated influenza vaccine (LAIV) has been approved. Objective: We aimed to evaluate the acceptance of nasally administered vaccines by parents of children with chronic illness, by comparing LAIV vs. injectable inactivated influenza vaccine (IIV) acceptance. Methods: We performed a retrospective, observational study (December 2014 to April 2015) including parents of all children vaccinated with the LAIV during the 2013-2014 influenza vaccination campaign at our university hospital. It was an opinion survey on the tolerance and acceptance of the LAIV. Results: A standardized evaluation form was completed by 67/79 parents of all children who received the LAIV (mean age: 113 +/- 56 months; 64% with a chronic respiratory disease). The parents responded that vaccines in general were important (99%) but only 58% of them accepted the injectable route of administration. Of the 48 parents of children who had received both LAIV and IIV in the past, global opinion (P < 0.0001) and tolerance (P < 0.0001) were better for LAIV. For the future, 81% of parents would prefer LAIV, mainly because of needle absence and/or less painful character, and 18% IIV, mainly because of easier administration or habit. Conclusion: The better acceptance of a nasally administrated vaccine could increase vaccination coverage in the future for nasal vaccines. (C) 2018 Elsevier Masson SAS. All rights reserved.